326 related articles for article (PubMed ID: 17352166)
1. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
4. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
5. [Solitary peritoneal carcinomatosis in prostate cancer].
Brehmer B; Makris A; Wellmann A; Jakse G
Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
[TBL] [Abstract][Full Text] [Related]
6. [Total androgen blockade].
Namiki M; Mizokami A
Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
[No Abstract] [Full Text] [Related]
7. [Reevaluation of MAB therapy and progress of endocrine therapy].
Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
[No Abstract] [Full Text] [Related]
8. [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
Barbón JJ; González-Tuero J; Gay LL; Pérez-García FJ; Sampedro A
Arch Soc Esp Oftalmol; 2007 Nov; 82(11):715-7. PubMed ID: 17979041
[TBL] [Abstract][Full Text] [Related]
9. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
10. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
Matveev BP; Bukharkin BV
Urologiia; 2001; (6):20-1. PubMed ID: 11785074
[No Abstract] [Full Text] [Related]
12. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
Okegawa T; Nutahara K; Higashihara E
Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
[TBL] [Abstract][Full Text] [Related]
13. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
Molenaar JP; Baten A; Blokx WA; Hoogendam A
Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417
[TBL] [Abstract][Full Text] [Related]
14. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
15. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
Lau YK; Chadha MK; Litwin A; Trump DL
J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
[TBL] [Abstract][Full Text] [Related]
16. [Endocrine therapy for prostate cancer in the future].
Usami M
Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.
Oh WK; Kaplan ID; Febbo P; Prisby J; Manola J; Kaufman DS; Kantoff PW
Am J Clin Oncol; 2003 Jun; 26(3):312-6. PubMed ID: 12796607
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
19. Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen.
Gandhok N; Sartor O
Urology; 2004 Oct; 64(4):807-9. PubMed ID: 15491730
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Sartor O
J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
